{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06285422",
            "orgStudyIdInfo": {
                "id": "SC262-101"
            },
            "organization": {
                "fullName": "Sana Biotechnology",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)",
            "officialTitle": "A Phase 1 Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin's Lymphoma (VIVID)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-evaluating-in-subjects-with-r-r-non-hodgkin-s-lymphoma-vivid"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-03",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-22",
            "studyFirstSubmitQcDate": "2024-02-22",
            "studyFirstPostDateStruct": {
                "date": "2024-02-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sana Biotechnology",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "SC262-101 is a Phase 1 study to evaluate SC262 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.",
            "detailedDescription": "This is an open-label, single arm, Phase 1, first-in-human (FIH) study to evaluate the safety and tolerability of SC262 administered intravenously (IV) following a standard lymphodepleting chemotherapy regimen of cyclophosphamide and fludarabine in subjects with Non Hodgkin's Lymphoma (NHL) who have received no more than 1 prior CD19-directed Chimeric Antigen Receptor T-Cells (CAR T) cell therapy. This study will be conducted in 2 parts. Dose finding using a 3+3 design in subjects with NHL. Dose expansion to further evaluate safety and efficacy at the recommended phase 2 dose (RP2D) in subjects with Large B-Cell Lymphoma (LBCL)."
        },
        "conditionsModule": {
            "conditions": [
                "Non Hodgkin's Lymphoma",
                "Large B-cell Lymphoma"
            ],
            "keywords": [
                "Large B-Cell Lymphoma",
                "CAR T Cell Therapy",
                "Mantle Cell Lymphoma",
                "Follicular Lymphoma",
                "Marginal Zone Lymphoma",
                "High-Grade B-Cell Lymphoma",
                "Primary Mediastinal B-Cell Lymphoma",
                "Diffuse Large B-Cell Lymphoma",
                "Non-Hodgkin's Lymphoma",
                "Allogeneic",
                "Hypoimmune",
                "CD22",
                "SC262"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 35,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "SC262 Plus Chemotherapy Regimen",
                    "type": "EXPERIMENTAL",
                    "description": "A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC262",
                    "interventionNames": [
                        "Drug: SC262"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "SC262",
                    "description": "SC262 is an allogeneic CAR -T cell therapy",
                    "armGroupLabels": [
                        "SC262 Plus Chemotherapy Regimen"
                    ],
                    "otherNames": [
                        "Cyclophosphamide",
                        "Fludarabine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Evaluate safety and tolerability of SC262",
                    "description": "Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities",
                    "timeFrame": "24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Evaluate preliminary anti-tumor activity of SC262",
                    "description": "Preliminary anti-tumor activity: Proportion of subjects with an objective response (including partial response or complete response)",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Evaluate cellular kinetics and persistence of SC262",
                    "description": "Cellular kinetics related peak (Cmax) in peripheral blood",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Evaluate cellular kinetics and persistence of SC262",
                    "description": "Cellular kinetics-related parameters evaluated by CAR T cell copy number",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Evaluate cellular kinetics and persistence of SC262",
                    "description": "Area under the concentration time curve (AUC) in peripheral blood",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Evaluate host immunogenicity to SC262",
                    "description": "Incidence of anti-CD19-directed CAR antibodies",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or Female Subject aged 18-80 years at the time of signing the informed consent\n2. Histologic diagnosis of NHL (based on World Health Organization 2016 criteria) including:\n\n   * LBCL, including Diffuse Large B Cell Lymphoma (DLBCL) not otherwise specified (NOS) (including DLBCL arising from indolent lymphoma), Primary Mediastinal Large B-Cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma (HGBCL), and Follicular Lymphoma (FL) Grade 3B\n   * FL\n   * Marginal Zone Lymphomas (MZL)\n   * Mantle Cell Lymphoma (MCL)\n3. Relapsed or refractory disease after no more than 1 prior CD19-directed CAR T cell therapy\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n5. At least 1 measurable (PET-positive) lesion per Lugano classification\n6. Life expectancy \u226512 Weeks\n\nExclusion Criteria:\n\n1. Prior CD22-directed therapy including CD22-directed CAR T cell therapy or other CD22 -directed antibody or cell therapy (e.g., Natural Killer (NK) cell)\n2. History of central nervous system (CNS) involvement of lymphoma within 1 year prior to enrollment.\n3. Autologous hematopoietic stem cell transplantation (HSCT) within 3 months before treatment with Lymphodepleting (LD) chemotherapy (or allogeneic HSCT at any time)\n4. Active autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy (defined as \\>10 mg/day prednisone or equivalent)\n5. History or presence of CNS disorder, such as seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement, within 12 months of enrollment.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Ndidi Onwudiwe",
                    "role": "CONTACT",
                    "phone": "(206) 791 3731",
                    "email": "vivid@sana.com"
                },
                {
                    "name": "Barbara Martello",
                    "role": "CONTACT",
                    "email": "vivid@sana.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Paul Brunetta, MD",
                    "affiliation": "Sana Biotechnology, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Swedish Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tori Braun",
                            "role": "CONTACT",
                            "email": "tori.braun@swedish.org"
                        },
                        {
                            "name": "Emily Murakami",
                            "role": "CONTACT",
                            "email": "emily.murakami@swedish.org"
                        },
                        {
                            "name": "Krish Patel, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18831",
                    "name": "Lymphoma, Large B-Cell, Diffuse",
                    "relevance": "LOW"
                },
                {
                    "id": "M11221",
                    "name": "Lymphoma, Follicular",
                    "relevance": "LOW"
                },
                {
                    "id": "M22307",
                    "name": "Lymphoma, Mantle-Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M20554",
                    "name": "Lymphoma, B-Cell, Marginal Zone",
                    "relevance": "LOW"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Non-Hodgkin Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1866",
                    "name": "Diffuse Large B-Cell Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T2361",
                    "name": "Follicular Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T3601",
                    "name": "Mantle Cell Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T3612",
                    "name": "Marginal Zone Lymphoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}